| Market Cap | 34.88M | P/E | - | EPS this Y | 37.10% | Ern Qtrly Grth | - |
| Income | -8.31M | Forward P/E | -14.29 | EPS next Y | 24.60% | 50D Avg Chg | 6.00% |
| Sales | 32.73M | PEG | -0.07 | EPS past 5Y | - | 200D Avg Chg | 5.00% |
| Dividend | N/A | Price/Book | 1.81 | EPS next 5Y | 25.00% | 52W High Chg | -28.00% |
| Recommedations | 2.00 | Quick Ratio | 0.78 | Shares Outstanding | 4.17M | 52W Low Chg | 35.00% |
| Insider Own | 2.91% | ROA | -6.79% | Shares Float | 1.68M | Beta | 1.37 |
| Inst Own | 60.38% | ROE | -62.97% | Shares Shorted/Prior | 2.56K/1.90K | Price | 1.00 |
| Gross Margin | 54.30% | Profit Margin | -25.40% | Avg. Volume | 7,900 | Target Price | 16.00 |
| Oper. Margin | -5.76% | Earnings Date | Nov 12 | Volume | 2,108 | Change | 6.38% |
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
| CG Capital | Outperform | May 16, 23 |
| HC Wainwright & Co. | Buy | Nov 3, 20 |
| HC Wainwright & Co. | Neutral | Mar 17, 20 |
| Ladenburg Thalmann | Buy | Dec 9, 19 |
| Oppenheimer | Outperform | Nov 21, 19 |
| Northland Capital Markets | Outperform | Dec 10, 18 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gov Shmuel | COO COO | Dec 05 | Buy | 0.46 | 20,000 | 9,200 | 20,000 | 12/05/23 |
| Rubinstein Samuel | Director Director | Nov 20 | Sell | 0.32 | 1,000 | 320 | 177,602 | 11/20/23 |
| 22NW, LP | 10% Owner 10% Owner | Aug 16 | Buy | 0.5521 | 1,853,056 | 1,023,072 | 5,369,954 | 08/18/23 |
| Rubinstein Samuel | Director Director | Jun 15 | Buy | 1.04 | 1,050 | 1,092 | 106,783 | 06/15/22 |
| Humphries William D. | Director Director | Mar 25 | Buy | 1.7336 | 16,950 | 29,385 | 484,440 | 03/28/22 |
| Humphries William D. | Director Director | Mar 24 | Buy | 1.582 | 14,783 | 23,387 | 467,490 | 03/24/22 |
| Moccia Robert Joseph | Chief Executive Offi.. Chief Executive Officer | Mar 24 | Buy | 1.5735 | 33,300 | 52,398 | 1,665,890 | 03/24/22 |